Particulars	eet as at March 31, 2016 Note	LKR-Thou	isands	INR-Tho	usands
	No.			arch 31,	
		2016	2015	2016	2015
QUITY AND LIABILITIES:					
Shareholders' Funds:					
Share Capital	1	1,990	1,000	955	49
Reserves and Surplus	2	(1,173)	(783)	(563)	(38
		817	217	392	1(
Current Liabilities:	2		40	12	
Other Current Liabilities	3	88	43	42	1
Total ASSETS:		905	260	434	1:
Non-Current Assets:					
Long Term Loans and Advances	4	15	15	7	
Current Assets:	4	15	10	(
Cash and Bank Balances	5	862	216	414	1(
Other Current Assets	6	28	210	13	
	0	890	245	427	12
Total		905	260	434	1:
Significant Accounting Policies	11				
Notes to the Financial Statements	1 to 16				
	oss for the year ended March 31,		aanda	ucondo	
Particulars	Note	LKR-Thousands INR-Thou Year ended March 31,			usanus
	No.	2016	2015	2016	2015
EXPENSES:					
Finance Costs	9	1	1	-	-
Other Expenses	10	389	237	183	1
Total Expenses		390	238	183	1
Loss for the year		(390)	(238)	(183)	(1
Basic & Diluted Earning per Share [EPS]	13	(3.90)	(2.38)	(1.83)	(1.1
Significant Accounting Policies	11				
Notes to the Financial Statements	1 to 16				
s per our report of even date		For a	nd on behalf	of the Board	
For Mukesh M. Shah & Co.,		<u></u>			
Chartered Accountants					
Firm Registration Number: 106625W					
Chandresh S. Shah					
Chandresh S. Shah Partner				Director	
				Director	

ZYDUS LANKA (PRIVATE) LIMITED				
omp	any overview:			
Tow	is Lanka (Private) Limited [the Company] was incorporated on April 11, 2011. The Company's registered office is situated at Level 26 and 34, East er, World Trade Centre, Echelon Square, Colombo - 01, Sri Lanka. The Company is formed with an object of distribution and selling of maceutical products in Sri Lanka. The company has not started its commercial operations during the year.			
	ficant Accounting Policies:			
1	Basis of Accounting:			
	The Financial Statements have been prepared in accordance with the Sri Lanka Financial Reporting Standards for Small & Medium sized Entities[SLFRS for SMEs]. Where appropriate, the policies and any changes thereto are explained in the succeeding notes.			
2	Statement of Compliance:			
	The Financial Statements have been prepared in accordance with the SLFRS for SMEs issued by the Institute of Chartered Accountants of Sri Lanka and the requirements of the Companies Act No. 07 of 2007.			
3	Reporting Currency Translation:			
	The Local accounts are maintained in local and functional currency which is "Sri Lankan Rupee". These accounts have been translated in Indian Rupees [INR] considering the operation of the Company as "Non-integral operations" for holding company. The translation of Financial Statements to INR from "Sri Lankan Rupee" is performed for assets and liabilities using the exchange rate prevailing on the Balance sheet date and for revenue and expenses using the average exchange rate for the respective period. The gain or loss resulting from such translation is included in "Foreign Currency Translation Reserve" under Reserves and Surplus.			
4	Foreign Currency [Currency other than company's functional currency] Transactions:			
	A The transactions in foreign currencies are stated at the rates of exchange prevailing on the dates of transactions.			
	B The net gain or loss on account of exchange differences either on settlement or on translation are recognised in the Statement of Profit and Loss.			
	C Monetary assets and liabilities denominated in foreign currencies are translated into Sri Lankan Rupee at the rates of exchange ruling at the balance sheet date			
5	Post Balance Sheet Events			
	All material events occurring after the Balance Sheet date have been considered and where necessary adjustments to or disclosure have been made in the Financial Statements.			
6	Income Tax Income Tax has been computed in accordance with the Provisions of Inland Revenue Act No. 10 of 2006 and amendments thereto.			
7	Liabilities and Provisions All known liabilities have been provided in preparing the Financial Statements.			
8	Provision for Retiring Gratuity No provision has been made for Retiring Gratuity since there are no permanent employees.			
9	Provisions, Contingent Assets and Contingent Liabilities Provisions are made for all obligations existing as at the Balance Sheet date when it is probable that such an obligation will result in an outflow of resources and a reliable estimate can be made of the quantum of the outflow.			
10	Expenditure			
	A All expenditure incurred on running of the business and for maintaining the capital assets in a state of efficiency has been charged to			

A All expenditure incurred on running of the business and for maintaining the capital assets in a state of efficiency has been charged to revenue in arriving at the profit or loss for the year.

Notes to the Financial Statements				
	LKR-Thou	usands	INR-Thousands	
		As at Ma	irch 31,	
Note: 1-Share Capital:	2016	2015	2016	2015
Authorised:				
199,000 Ordinary shares [as at March 31, 2015: 100,000] of LKR 10/- each	1,990	1,000	955	49
	1,990	1,000	955	49
Issued, Subscribed and Paid-up:				
199,000 Ordinary shares [as at March 31, 2015: 100,000] of LKR 10/- each, fully paid up	1,990	1,000	955	49
A The reconciliation of the number of Shares outstanding is as under:	1,990	1,000	955	49
Particulars				
Number of Shares at the beginning of the year	100,000	100,000		
Add: Shares issued during the year	99,000	0		
Number of Shares at the end of the year	199,000	100,000		
B The Company has only ordinary shares. All ordinary shares rank parri passu and				
carry equal rights with respect to voting and dividend. In the event of liquidation of				
the Company, the shareholders shall be entitled to proportionate share of their holding in the assets remained after distribution of all preferential amounts.				
holding in the assets remained after distribution of all preferential amounts. C Ordinary shares of LKR 10/- each, fully paid held by Holding Company, Cadila Healthcare Limited,				
a company incorporated in India:				
Number of Shares	199,000	100,000		
% to total share holding	100%	100%		
Note: 2-Reserves and Surplus:				
Foreign Currency Translation Reserve: [*]			(11)	
Balance as per last Balance Sheet Add/ [Less]: Exchange differences on translation to Indian Rupee			(11) 4	-
Add/ [Less]. Exchange differences on translation to Indian Rupee	_	-	(7)	(
Surplus in statement of Profit and Loss:	_		(1)	(
Balance as per last Balance Sheet	(783)	(545)	(373)	(2
Add: [Loss] for the year	(390)	(238)	(183)	(1
Balance as at the end of year	(1,173)	(783)	(556)	(3
Total	(1,173)	(783)	(563)	(3
Note: 3-Other Current Liabilities:				
Provision for Expenses	88	43	42	
Total	88	43	42	
Note: 4-Long Term Loans and Advances:				
Others : Security Deposits - Rent	15	15	7	
Total	15	15	7	
		10		
Note: 5-Cash and Bank Balances:				
Balance with Bank	862	216	414	10
Total	862	216	414	1
Note : 6 - Other Current Assets :				
Prepaid Expenses	28	29	13	
Total	28	29	13	
Note: 7-Contingent Liabilities:				
There were no material contingent liabilities outstanding as at the date of the Balance Sheet.				
Note: 8-Capital Commitments:				
There were no capital expenditure commitments approved as at 31st March, 2016 in respect of the Company	·.			
	LKR-Thousands		INR-Thousands	
	Y	ear ended	March 31,	
	2016	2015	2016	2015
Note: 9-Finance Cost: Bank Commission & charges	1	1	-	-
Total	1	1	-	-
Note: 10-Other Expenses:	044	10/	101	
Legal and Professional Fees Rent	214 68	126 68	101 32	
Miscellaneous Expenses [*]	107	43	50	
Total	389	237	183	1
[*] Miscellaneous Expenses include Payment to the auditors	24	24	41	
	34 9	34 9	16 4	

ZYDUS LANKA (PRIVATE) LIMITED

1

Note: 11 - Taxetion: Note: 11 - Taxetion: Image: Instant income the staft Bit context PBIK on the stands income. Image: Image	
A The Company is liable to income tax at 28% on the taxable income. B However to providen for income tax, has been made for the variant direct there is no taxable income. C Three exists a temporary difference between the local income and tax horner because of carried forward bases as par income tax. However the the states. There is states. There exists a temporary difference between the local income and tax horner because of carried forward bases as par income tax. However the the states as the more bounders and the commerced and recommended and recommend and recommend and recommend and recommended and recommend and rec	
There has been no material event occurring after the Balance Sheel date that requires adjustment to or disclosure in the Financial Statements. INR. Th INR. Th Note: 13-Calculation of Earnings per Share (EPS): INR. Th A Loss altributable to Shareholders 2016 <	
Like: Like: Like: Note: 3 at March 31. Note: 13.Calculation of Earnings per Share [EPS]: 2016 2015 2016 2015 2016 2015 2016 2015 2016	
As at Watch 31, As at Watch 31, As at Watch 31, A local calculation of Earnings per Share (EPS): 2016 <td></td>	
As at Watch 31, As at Watch 31, As at Watch 31, A local calculation of Earnings per Share (EPS): 2016 <td>ousands</td>	ousands
The numerators and denominators used to calculate the basic and diluded EPS are: (390) (230) (183) Basic and Weighted average number of shares outstanding during period Numbers (390) (230) (183) C Nominal value of share 100,000 100,000 100,000 100,000 100,000 D Basic and Weighted average number of shares outstanding during period 10 10 (183) Note: 14-Related Party Transactions: 10 10 (183) (183) Note: 14-Related Parties and Mature of the Related Party Relationship: a Holding Company: Calila Healthcare Limited Zydus Pharmaceuticals (USA) Inc. [USA] Diafrohealth India Limited Zydus Pharmaceuticals (USA) Inc. [USA] Diafrohealth India Limited Zydus Noveltech Inc. [USA] Diafrohealth India Limited Zydus Alextrace (USA) LC. [USA] Ediafrohealth India; Limited Zydus Noveltech Inc. [USA] More: Yadu Technologis Limited Zydus Moveltech Inc. [USA] Samya Pharmaceutical Kalika Samya Pharmaceutical Kalika Alder Pharmaceuticals Limited Samya Pharmaceutical Kalika Samya Pharmaceutical Kalika Zydus Flames (Systical Kalika) Samya Pharmaceutical Kalika Alder Pharmaceuticals Limited Samya Pharmaceutical Kalika Zyd	
A Loss attributable to Shareholders (1990) (23) (183) B Basic and Weighted average number of shares outstanding during period (1990) (23) (183) Numbers (16, 2000) (20, 2000)	2015
B Basic and Weighted average number of shares outstanding during period Numbers 100,000 100,000 00,000	
LKR In 0 Basic & Diluted EPS 10 <	
C Nominal value of share 10	100,0
D Basic & Diluted EPS (3.90) (2.30) (1.83) Note: 14-Related Party Transactions: A Mame of the Related Parties and Nature of the Related Party Relationship: A Holding Company: Cadla Healthcare Limited Edition Subsidiar/est Concerns: Diaforhealth India Limited Zydus Pharmaceuticals (USA) I.C. (USA) Diaforhealth Unity Limited Nesher Pharmaceuticals (USA) I.C. (USA) Diaforhealth Unity Limited Zydus Heathcare (USA) I.C. (USA) Types Wellness Limited Zydus Heathcare (USA) I.C. (USA) Types New York (USA) Types New York (USA) Types Wellness Limited Zydus Heathcare (USA) I.C. (USA) Types New York (USA) Types New York (USA) Types Wellness Limited Zydus Wellness Sikkim, a Partnership Firm Zydus Nikho Farmaccuticals (USA) Types New York (USA) Types Wellness Limited Zydus Nikho Farmaccuticals Mexico Sonce (V Mexico) Zydus Nikho Farmaccuticals Mexico Sonce (V Mexico) Zydus Beathcare, a Partnership Firm Laboratorics Combards S.L. (Bpain) Zydus New York New York (USA) Zydus New York (USA) Zydus New Heathcares Suppose New York (USA) Zydus New York (USA) Zydus New York (USA) Zydus New York New York (USA) Zydus New York (USA) Zydus New York (USA) Zydus New York (USA) Zydus New	
A Name of the Related Parties and Nature of the Related Party Relationship: a Holding Company: Cadila Healtneare Limited b Fellow Subsidiaries/ Concerns: Dialforhealth India Limited Zydus Pharmaceuticals (USA) Inc. [USA] Dialforhealth India Limited Zydus Healtneare Limited Dialforhealth India Limited Zydus Healtneare (USA) LLC (USA) Dialforhealth Creencross Limited Zydus Healtneare (USA) LLC (USA) German Remedies Limited Zydus Healtneare SA. (Pty) Ltd (South Africa) Zydus Technologies Limited Simayla Pharmaceutical (LG (USA) Zydus Technologies Limited Simayla Pharmaceutical (LG (USA) Zydus Technologies Limited Simayla Pharmaceutical (LG (USA) Zydus Technologies Limited Zydus Nethones Provide (LG (South Africa) Zydus Technologies Limited Zydus Nethones Provide (LG (South Africa) Zydus BSV Pharma Private Limited Zydus Nethones Services (Pty) Ltd (South Africa) Zydus BSV Pharma Private Limited Zydus Nethones Services (Pty) Ltd (South Africa) Zydus BSV Pharma Private Limited Zydus Nethones Services (Pty) Ltd (South Africa) Zydus Nethonearchice, Pharmaceutical Industries Limited Zydus Nethones Services (Pty) Ltd (South Africa) Zydus Isotherane, SN (Thre Nethoriands) Zydus Nethonearchices Nethones Servi	(1.
A Name of the Related Parties and Nature of the Related Party Relationship: a Holding Company: Cadita Heathcare Limited b b Fellow Subsidiaries/ Concerns: Dialforheath India Limited Zydus Pharmaceuticals (USA) Inc. [USA] Dialforheath India Limited Zydus Heathcare Limited Dialforheath Creations Stimled Zydus Heathcare Limited Zydus Welless: Stimled Zydus Heathcare Limited Zydus Welless: Stimled Hercon Pharmaceutical (USA) LC (USA) Liva Pharmaceutical Limited Simayla Pharmaceutical (USA) Zydus Technologies Limited Simayla Pharmaceutical (Li [South Africa] Zydus Technologies Limited Zydus Nathon Samaceutical (Li [South Africa] Zydus Technologies Limited Zydus Nathon Samaceutical (Li [South Africa] Zydus BSV Pharma Private Limited Zydus Nathon Samaceutical (Ling) Zydus International Private Limited Zydus Nathon Samaceutical Maxico Sance Company SA De C.V. [Mexico] Zydus International Private Limited Zydus Pharmaceutical Maxico Sance Company SA De C.V	
a Holding Company: Cadla Healthcare Limited b Fellow Subsidiaries/ Concerns: Diaforhealth India Limited Zydus Pharmaceuticals (USA) Inc. [USA] Diaforhealth India Limited Nesher Pharmaceuticals (USA) LLC [USA] Diaforhealth India Limited Diaforhealth India Limited Zydus Newtenion.c. [USA] Diaforhealth India Limited Comman Remedical Science Zydus Newtenion.c. [USA] Diaforhealth India Limited Zydus Wellness-Sikkim, a Partnership Firm Zydus Healthcare SA (Pty) Ltd [South Africa] Use Pharmaceuticals Limited Simayla Pharmaceuticals (Drey) Ltd [South Africa] Zydus Stechnologies Limited Sirip Management Services (Pty) Ltd [South Africa] Zydus Stechnologies Limited Zydus Fince, SAS (France) Alidac Pharmaceutical Industries Limited Zydus Pharmapeane Co. Ltd. [Brazil] Zydus Stechnologies Limited Zydus Pharmapeane Co. Ltd. [Brazil] Zydus Beathcare Philippines Inc. [Philippines] Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico] Zydus Beathcare Philippines Inc. [Philippines] Zydus Worldwelde Sorvice Sorompany SA De C.V.[Mexico] Zydus International Private Limited [Ireland] Zydus Worldwelde Sorvice Sorompany SA De C.V.[Mexico] Zydus Internations Brite Internated Mr. Tushar Shroff Transoctio	
Cadila Healthcare Limited	
b Fellow Subsidiaries/ Concerns: Diatorhealth India Limited Zydus Pharmaceuticals (USA) Inc. [USA] Diatorhealth Greencoss Limited Zydus Healthcare (USA) LLC [USA] Cernan Remedies Limited Zydus Newtech Inc. [USA] Zydus Wellness Limited Hercon Pharmaceuticals (USA) LLC [USA] Zydus Wellness Limited Hercon Pharmaceuticals (Py) Ltd [South Africa] Zydus Meeliness Sikkim, a Partnership Firm Zydus Healthcare SA. (Py) Ltd [South Africa] Zydus Technologies Limited Simited Simited Siript Management Services (Pt)) Ltd [South Africa] Zydus Six Technologies Limited [Formerly known as Zydus Parma Sec (Pt) Ltd [South Africa] Zydus Six Pharma Phrvate Limited [Formerly known as Zydus Pharma Ceutical Kuda. [Brazil] Zydus Six Pharma Phrvate Limited [Formerly known as Zydus Pharma Japan Co. Ltd. Japan] Mix 2ydus Healthcare, Partnership Firm Laboratorios Combis S.L. [Spain] Zydus BSV Pharma Phrvate Limited [Tearnership Firm Laboratorios Combis S.L. [Spain] Zydus BSV Pharma Phrvate Limited [Tearnership Firm Laboratorios Combis S.L. [Spain] Zydus Netherlands BV. [the Netherlands] Zydus Discovery DMCC [Dubai] Bremer Pharma GmbH [Germany] C Directors: Mr. Ashok Bhatia Mr. Tushar Shroff D Transactions with Related Parties: Nature of Transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions with parties referred to in Note 14-A [b & c] Metric 5-Segment Linformation: The Information: The Information on segment Is not applicable as there are no revenue from operations. Metric 5-Segment Information: The Information on segment Is not applicable as there are no revenue from operations. Metric 5-Segment Information: Previ	
biatrohealth India Limited Zydus Pharmaceuticals (USA) ILC [USA] Diatrohealth Greencross Limited Zydus Noveltech Inc. [USA] German Remedies Limited Zydus Noveltech Inc. [USA] Cydus Wellness-Stekkim, a Partnership Firm Zydus Healthcare (USA) LLC [USA] Witz Pharmaceuticals LUINA Liva Pharmaceuticals LUINA Biochem Pharmaceuticals Industries Limited Zydus Strate Pharmaceuticals Method Liva Pharmaceuticals Method Liva Pharmaceuticals Method Liva Pharmaceuticals Method Liva Pharmaceuticals Mexico Sta De CV [Moxico] Zydus Isternational Private Limited [Ireland] Zydus Heathcare Philippines In: [Philippines] Zydus Weathcare Philippines In: [Philippines] Zydus Method Hotherinands] Zydus Method Hotherinands] Zydus Method Hotherinands] Zydus Method Hotherinands] Zydus Method Hotherinands] Zydus Worldwide DMCC [Dubai] ZAHL Europe B.V. [the Netherinands] Bremer Pharma GmbH [Germany] C Directors: Mr. Ashok Bhatia Mr. Tushar Shroff Mr. Ashok Bhatia Mr. Tushar Shroff Mr. Ashok Bhatia Mr. Tushar Shroff Mr. Ashok Bhatia Mr. In Note 14-A [a] Nature of Transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [b & c] Note: 6 Dreve were no transactions with parties referred to in Note 14-A [b & c] Net: 16 Provious Vear fliques Previous year's fliqures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Net: 16 Provious Vear fliques Previous year's f	
Diaforhealth Unity Limited Nesher Pharmaceuticals (USA) LLC (USA) Diaforhealth Greencoss Limited Zydus Healthcare (USA) LLC (USA) Zydus Wellness Limited Zydus Newtelch Inc. [USA] Mix Sydus Wellness Limited Hercon Pharmaceuticals LLC (USA) Mix Sydus Wellness Limited Simayla Pharmaceuticals LLC (USA) Mix Sydus Wellness Limited Simayla Pharmaceuticals LLC (USA) Biochem Pharmaceuticals Limited Simayla Pharmaceuticals CNP) Ltd (South Africa) Zydus Sixth Pharmaceuticals Limited Simayla Pharmaceuticals (River) NL (South Africa) Biochem Pharmaceuticals Limited Sirayla Pharmaceuticals (River) NL (South Africa) Zydus Sixth Pharmaceuticals Limited Sirayla Pharmaceuticals (River) NL (South Africa) Zydus Netherlands I Industries Limited Zydus Sixth Pharmaceuticals (River) NL (South Africa) Zydus Netherlands I Industries Limited Zydus Pharmaceuticals Mexico SA De CV (Mexico) Zydus Netherlands NV (The Netherlands) Etna Biotech S R.L. (Italy) Zydus Netherlands NV (The Netherlands) Zydus Worldwide DMCC (Dubai) Zydus Netherlands Zydus Netherlands Zydus Netherlands Zydus Netherlands Zydus Netherlands Zydus Netherlands Zydus Netherlands Zydus Netherlands	
Diaforhealth Greencess Limited Zydus Healthcare (USA) LLC [USA] German Remedies Limited Zydus Novellech Inc. [USA] Vzydus Welleness-Sikkim, a Partnership Firm Zydus Healthcare (S.A. (Pb) Ltd [South Africa] Liva Pharmaceuticals Limited Smayle Pharmaceuticals (Pb) Ltd [South Africa] Zydus Teance, SAS [France] Bitchem Pharmaceutical Industries Limited Zydus France, SAS [France] Alidace Pharmaceutical Industries Limited Zydus Pharmaceuticals Limited [Formerly known as Zydus Pharmaceuticals Limited [Formerly known as Zydus BSV Pharma Private Limited [Formerly known as Zydus Pharmaceuticals Mexico So De CV [Mexico] Velocico] Zydus International Private Limited [Formerly known as Zydus Pharmaceuticals Mexico So De CV [Mexico] Velocico] Zydus International Private Limited [Formerly known as Zydus Pharmaceuticals Mexico So De CV [Mexico] Velocico] Zydus International Private Limited [Formerly known as Zydus Pharmaceuticals Mexico So De CV [Mexico] Velocico] Zydus International Private Limited [Formerly known as Zydus Pharmaceuticals Mexico So De CV [Mexico] Velocico] Zydus International Private Limited [Formerly known as Zydus Pharmaceuticals Mexico So De CV [Mexico] Velocico] Zydus International Private Limited [Formerly known as Zydus Pharmaceuticals Mexico So De CV [Mexico] <td></td>	
Zydus Wellness Limited Hercon Pharmaceuticals LiL (2 (USA) M/s. Zydus Wellness-Sikkin, a Partnership Firm Zydus Healthcare S.A. (Pty) Ltd [South Africa] Liva Pharmaceuticals Limited Simgly Pharmaceuticals (Pty) Ltd [South Africa] Zydus Technologies Limited Simgly Pharmaceuticals (Pty) Ltd [South Africa] Biochem Pharmaceutical Industries Limited Zydus Nikho Farmaceutica (Ltd., [Brazil] Alidac Pharmaceuticals Limited [Formerly known as Zydus Nikho Farmaceutica (Ltd., [Brazil] Xydus SQU BSZ Pharma Private Limited [Terlent] Zydus Nikho Farmaceutica Mexico Services Company SA De C. V. [Mexico] Zydus International Private Limited [Irelent] Zydus Worldwide DMCC [Dubai] Zydus International Private Limited [Irelent] Zydus Worldwide DMCC [Dubai] Zydus Netherlands SJ. (The Netherlands] Etna Biotech S.R.L. [Itay] Zydus Netherlands SJ. (The Netherlands] Zydus Worldwide DMCC [Dubai] Zydus Netherlands SJ. (The Netherlands] Zydus Norldwide DMCC [Dubai] Brener Pharma GmbH [Germany] Zydus Stroner C Directors: Mr. Ashok Bhatia Mr. Tushar Shroff B Tansactions with Related Parties: Iter and data March 31 2016 2016 2016 2016 2016 2016 2016 2016 2016 201	
Ms. Zydus Wellness-Sikkim, a Partnership Firm Zydus Healthcare S.A. (Pty) Ltd [South Africa] Liva Pharmaceuticals Limited Simajd Pharmaceuticals (Pty) Ltd [South Africa] Zydus Technologies Limited Script Management Services (Pty) Ltd [South Africa] Bicchem Pharmaceuticals Limited Zydus France, SAS [France] Alidac Pharmaceuticals Limited [Formerly known as Zydus Nikkho Farmaceutica Lde. [Brazil] Zydus BSV Pharma Private Limited] Zydus Nikkho Farmaceuticals Mexico SAS [France] Zydus Healthcare, a Partnership Firm Laboratorios Combits SL. [Spain] Zydus Netherlands B.V. (the Netherlands] Zydus Pharmaceuticals Mexico SAD EC V [Mexico] Zydus Netherlands B.V. (the Netherlands] Zydus Netherlands B.V. (the Netherlands] Zydus Netherlands B.V. (the Netherlands] ZAHL E.V., (the Netherlands] Zydus Nordwide DMCC [Dubai] Zydus Netherlands B.V. (the Netherlands] Zydus Netherlands B.V. (the Netherlands] Bremer Pharma GmbH [Germany] Ena Biotech S.R.L. [Italy] Year ended March 31 Bremer Pharma GmbH [Germany] Z016	
Liva Pharmaceuticals Limited Simayla Pharmaceuticals (Pty) Ltd [South Africa] Zydus Technologies Limited Zydus France, SAS [France] Alidac Pharmaceutical Industries Limited Zydus France, SAS [France] Alidac Pharmaceuticals Limited [Ormerty known as Zydus Nikkho France, SAS [France] Zydus SVP harma Private Limited] Zydus Pharma Japan Co. Ltd. [Japan] Kws. Zydus Healthcare, a Partnership Firm Laboratorios Combit S.L. (Spain] Zydus Healthcare, a Partnership Firm Laboratorios Combit S.L. (Spain] Zydus Healthcare, Philippines Inc. [Philippines] Zydus Pharmaceuticals Mexico SA De CV (Mexico] Zydus Heartnational Private Limited [Ireland] Zydus Pharmaceuticals Mexico Sarvices Company SA De C.V.[Mexico] Zydus Netheriands B.V. [the Netheriands] Zydus Pharmaceuticals Mexico Sarvices Company SA De C.V.[Mexico] Zydus Netheriands B.V. [the Netheriands] Zydus Underweitig DMCC [Dubai] ZAHL E.V. [the Netheriands] Zydus Underweitig DMCC [Dubai] Bremer Pharma GmbH [Germany] C Directors: Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions with Related Parties: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions with parties referred to in Note 14-A [b & C] Net: 15-Segment Information: The Information on segment is not applicable as there are no revenue from operations. Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For and on behalf of the Board For Mukesh M. Shak & Co., Chartered Accountaris	
Zydus Technologies Limited Scripf Management Services (Pty) Ltd [South Africa] Biochem Pharmaceutical Industries Limited Zydus France, SAS [France] Alidac Pharmaceutical Industries Limited Zydus Pharma Japan Co. Ltd. [Japan] Zydus BSV Pharma Private Limited] Zydus Pharma Japan Co. Ltd. [Japan] M/s. Zydus Healthcare, Philippines] Zydus Pharmaceuticals Mexico SA De CV [Mexico] Zydus Netherands BV. (the Netherlands) Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico] Zydus Netherlands BV. (the Netherlands) Zydus Worldwide DMCC [Duba] ZAHL B.V. (the Netherlands) Zydus Worldwide DMCC [Duba] ZHL B.V. (the Netherlands) Zydus Worldwide DMCC [Duba] Brener Pharma GmbH [Germany] Ena Blotech S.R.L. [Italy] C Directors: mr. Ashok Bhatia Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions with Related Parties: The following transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] 92016 Nature of Transactions with parties referred to in Note 14-A [b & c] 2016 Shares Issued: Cadila Healthcare Limited 920 Cadila Healthcare Limited 990 4665 b There w	
Biochem Pharmaceutical Industries Limited Zydus Strance, SAS [France] Alidac Pharmaceuticals Limited [Formerly known as Zydus Nethon Farmaceutical Lida. [Brazill] Zydus SV Pharma Private Limited [Formerly known as Zydus Pharma Driven Lida. [Brazill] Zydus Healthcare, a Partnership Firm Laboratorios Combix S.L. [Spain] Zydus Healthcare, a Partnership Firm Laboratorios Combix S.L. [Spain] Zydus Netherlands B.V. [the Netherlands] Zydus Pharmaceuticals Mexico SAD De CV [Mexico] Zydus Netherlands B.V. [the Netherlands] Zydus Vorldwide DMCC [Dubal] ZAHL B.V. [the Netherlands] Zydus Strance Bremer Pharma GmBH [Germany] C C Directors: Mr. Ashok Bhatia Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions with Related Parties: Mr. Ashok Bhatia The following transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions Year ended March 3] 2016 Shares Issued: Cadila Healthcare Limited - Cadila Healthcare Limited - - b There were no transactions with parties referred to in Note 14-A [b & c] - Note: 15-Segment Information:	
Aldac Pharmaceuticals Limited [Formerly known as Zydus Nikkho Farmaceutica Ltda. [Brazil] Zydus SV Pharma Private Limited] Zydus Pharma Japan Co. Ltd. [Japan] Zydus Healthcare, a Partnership Firm Laboratorios Combix S.L. [Spain] Zydus Healthcare Philippines Inc. [Philippines] Zydus Pharmaceuticals Mexico SA De CV [Mexico] Zydus International Private Limited [Ireland] Zydus Netherlands Private Limited [Ireland] Zydus Netherlands] Zydus Netherlands] Zydus Netherlands] Zydus Voldwide DMCC [Duba] ZAHL B.V. [the Netherlands] ZAHL Europe B.V. [the Netherlands] ZAHL Europe B.V. [the Netherlands] Zydus Usicovery DMCC [Duba] ZAHL Europe B.V. [the Netherlands] Zydus Voldwide DMCC [Duba] Bermer Pharma GmbH [Germany] C Directors: Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions with Related Parties: The following transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions Cadila Healthcare Limited Details relating to parties referred to in Note 14-A [a] Nature of Transactions with parties referred to in Note 14-A [b & c] Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants	
M/s. Zydus Healthcare, a Partnership Firm Laboratorios Combix S.L. [Spain] Zydus Healthcare Philippines Inc. [Philippines] Zydus Pharmaceuticals Mexico SA De CV [Mexico] Zydus International Private Limited [Ireland] Zydus Pharmaceuticals Mexico Services Company SA De C.V. [Mexico] Zydus Netherlands B.V. [the Netherlands] EIna Biotech S.R.L. [Italy] ZAHL B.V. [the Netherlands] Zydus Vorldwide DMCC [Dubai] ZAHL Europe B.V. [the Netherlands] Zydus Vorldwide DMCC [Dubai] Bremer Pharma GmbH [Germany] C C Directors: Mr. Tushar Shroff Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions with Related Parties: Mr. Tushar Shroff Nature of Transactions Vera ended March 3] Nature of Transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions with parties referred to in Note 14-A [a] 2016 2015 2016 Shares Issued: Cadila Healthcare Limited 990 - 465 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] Year ended March 31 2016 990 - 465 - -	
Zydus Healthcare Philippines Inc. [Philippines] Zydus Pharmaceuticals Mexico S A De CV [Mexico] Zydus International Private Limited [Ireland] Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico] Zydus International Private Limited [Ireland] Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico] Zydus Netherlands B.V. (Ithe Netherlands] Zydus Worldwide DMCC [Dubai] ZAHL Europe B.V. [the Netherlands] Zydus Discovery DMCC [Dubai] ZAHL Europe B.V. [the Netherlands] Zydus Discovery DMCC [Dubai] B Transactions with Related Parties: mr. Tushar Shroff B Transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions KR-Tha Zo14 Zo15 Zo14 Cadila Healthcare Limited 990 - 465 2015 Zo14 Cadila Healthcare Limited 6 990 - 465 6 b There were no transactions with parties referred to in Note 14-A [b & c] 990 - 465 6 990 - 465 6 990 - 465 6 6 6 16 16 16 16 6 16 6	
Zydus International Private Limited [Ireland] Zydus Pharmaceuticals Mexico Services Company SA De C.V.[Mexico] Zydus Netherlands B.V. [the Netherlands] Etna Blotech S.R.L. [Italy] ZAHL B.V. [the Netherlands] Zydus Worldwide DMCC [Dubai] ZAHL B.V. [the Netherlands] Zydus Worldwide DMCC [Dubai] ZAHL B.V. [the Netherlands] Zydus Worldwide DMCC [Dubai] Bremer Pharma GmbH [Germany] Transactions with Related Parties: Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions INR-The Cadila Healthcare Limited 2016 2016 Cadila Healthcare Limited 2016 2016 2016 Deternation The information: 1 2016 2016 2016 Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Shares I statements Mote: 16-Previous Year figures: For and on behalf of the Board For and on behalf of the Board Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the	
Zydus Netherlands B.V. [the Netherlands] Eina Biotech S.R.L. [Italy] ZAHL B.V. [the Netherlands] Zydus Worldwide DMCC [Dubai] ZAHL B.V. [the Netherlands] Zydus Worldwide DMCC [Dubai] ZAHL Europe B.V. [the Netherlands] Zydus Discovery DMCC [Dubai] Bremer Pharma GmbH [Germany] Zydus Discovery DMCC [Dubai] Bremer Pharma GmbH [Germany] Mr. Tushar Shroff B Transactions with Related Parties: Mr. Tushar Shroff In following transactions were carried out with the related parties in the ordinary course of business: INR-Th Nature of Transactions INR-Th Vear ended March 31 2016 2015 Shares Issued: Cadila Healthcare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] Vear ended March 31 2016 2015 2016 2015 2016 2015 2016 2015 2016 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 2016 2015 20	
ZAHL B.V. [the Netherlands] Zydus Worldwide DMCC [Dubai] ZAHL Europe B.V. [the Netherlands] Zydus Discovery DMCC [Dubai] Bremer Pharma GmbH [Germany] Sinserver Pharma GmbH [Germany] c Directors: Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions with Related Parties: Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions with Related Parties: Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions. INR-The Year ended March 31 2016 2015 2016 Cadila Healthcare Limited 990 - b There were no transactions with parties referred to in Note 14-A [b & c] Vear ended March 31 2016 2015 2016 990 - Cadila Healthcare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] Vear ended March 31 Vear ended Tarchare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] Vear ended March 31 Previous year's figures have been r	
ZAHL Europe B.V. [the Netherlands] Zydus Discovery DMCC [Dubai] Bremer Pharma GmbH [Germany] Bremer Pharma GmbH [Germany] c Directors: Mr. Ashok Bhatia Mr. Tushar Shroff B Transactions with Related Parties: The following transactions were carried out with the related parties in the ordinary course of business: a a Details relating to parties referred to in Note 14-A [a] Nature of Transactions. KR-Thousands Year ended March 31 2016 2016 2015 2016 Shares Issued: 2016 2015 2016 Cadila Healthcare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] 990 - 465 Note: 15-Segment Information:	
Bremer Pharma GmbH [Germany] C Directors: Mr. Ashok Bhatia Mr. Tushar Shroff Mr. Ashok Bhatia Mr. Tushar Shroff Mr. Ashok Bhatia Mr. Tushar Shroff I Transactions with Related Parties: The following transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions LKR-Thousands INR-Th Year ended March 31 2016 2015 2016 2015 2016 2016 2015 2016 201 201 201 201 201 201 201 201 201 201	
C Directors: Mr. Ashok Bhatia Mr. Tushar Shroff Matter Structure Struct	
B Transactions with Related Parties: The following transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] Nature of Transactions INR-The Year ended March 31 2016 2015 Cadila Healthcare Limited 990 b There were no transactions with parties referred to in Note 14-A [b & c] Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants	
The following transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] LKR-Thousands INR-The Nature of Transactions Year ended March 31 2016 2015 2016 Shares Issued: Cadila Healthcare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] 990 - 465 Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. - - - Note: 16-Previous Year figures: - - - - - - Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. -	
The following transactions were carried out with the related parties in the ordinary course of business: a Details relating to parties referred to in Note 14-A [a] LKR-Thousands INR-The Nature of Transactions Year ended March 31 2016 2015 2016 Shares Issued: Cadila Healthcare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] 990 - 465 Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. - - - Note: 16-Previous Year figures: - - - - - - Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. -	
a Details relating to parties referred to in Note 14-A [a] Nature of Transactions. LKR-Thousands INR-The Year ended March 31 2016 2015 2016 2015 2016 2016 2015 2016 2016 2015 2016 2016 2015 2016 990 - 465 Previous vear no transactions with parties referred to in Note 14-A [b & c] Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants	
Shares Issued: 2016 2015 2016 Cadila Healthcare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] 990 - 465 Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. - - - Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. - - Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants - -	
Shares Issued: 2016 2015 2016 Cadila Healthcare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] 990 - 465 Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. - - - Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. - - - Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants - -	ousands
Shares Issued: Cadila Healthcare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] 990 - 465 Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants	
Cadila Healthcare Limited 990 - 465 b There were no transactions with parties referred to in Note 14-A [b & c] -	<u>2015</u>
b There were no transactions with parties referred to in Note 14-A [b & c] Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For Mukesh M. Shah & Co., Chartered Accountants	
Note: 15-Segment Information: The information on segment is not applicable as there are no revenue from operations. Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants	-
The information on segment is not applicable as there are no revenue from operations. Note: 16-Previous Year figures: Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants	
Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants	
Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure. Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants	
Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants	
As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants	
As per our report of even date For and on behalf of the Board For Mukesh M. Shah & Co., Chartered Accountants	
For Mukesh M. Shah & Co., Chartered Accountants	
Firm Registration Number: 106625W	
Chandresh S. Shah	
Partner Directo	
Membership Number: 042132	
Ahmedabad, Dated: May 12, 2016	

	ZYDUS LANKA (PRIVATE) LIM Cash Flow Statement for the year ended								
Par	ticulars	LKR-Tho		INR-Thou	sands				
		Year ended March 31,							
		2016	2015	2016	2015				
Α	Cash flows from operating activities:								
	Loss before tax	(390)	(238)	(183)	(11)				
	Adjustments for:								
	Decrease/ [Increase] in long term advances		-	-	-				
	Decrease/ [Increase] in other current assets	1	-	-	-				
	Increase/ [Decrease] in other current liabilities	45	-	21	-				
	Total	46	-	21	-				
	Net cash from [used] operating activities	(344)	(238)	(162)	(111				
в	Cash flows from investing activities:								
	Net cash used [from] in investing activities		-		-				
С	Cash flows from financing activities:								
	Net cash used [from] in financing activities	990	-	465	-				
	Net increase in cash and cash equivalents	646	(238)	303	(11)				
	Increase/ [Decrease] due to the translation to INR [Refer Note-3]		-	5	(1				
	Cash and cash equivalents at the beginning of the year	216	454	106	218				
	Cash and cash equivalents at the end of the year	862	216	414	106				
	Notes to the Cash Flow Stater	ment							
1	All figures in brackets are outflows.								
2	Previous year's figures have been regrouped wherever necessary.								
3	Cash Flow Statement is translated into Indian Rupee [INR] at the average exchange rates for the year. The increase/ decrease resulting from								
	such translation is shown separately as "Increase/ [Decrease] due to the translation to INR"								
	As per our report of even date	For and on behalf of the Board							
	For Mukesh M. Shah & Co.,								
	Chartered Accountants								
	Firm Registration Number: 106625W								
	Chandresh S. Shah								
	Partner			Director					
	Membership Number: 042132								
	Ahmedabad, Dated: May 12, 2016								